CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $2.79M, lower than 95% of all stocks globally
- PositionGross margin is 100%, higher than 95% of its Biotechnology peers (median 67.2%)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
303.51MUSDvs all stocks (USD)
Revenue (TTM)
2.79MUSDvs all stocks (USD)
Beta
1.64xvs all stocks
52-Week Change
-74.23%vs all stocks
Market Capitalization
303.51MUSDvs all stocks (USD)
Enterprise Value
153.98MUSDvs all stocks (USD)
Forward P/E
-1.31xvs Biotechnology peers
Price to Book (MRQ)
1.85xvs Biotechnology peers
Enterprise to Revenue
55.23xvs Biotechnology peers
Enterprise to EBITDA
-0.4900xvs Biotechnology peers
Gross Margin
100.00%vs Biotechnology peers
Return on Assets (TTM)
-74.85%vs Biotechnology peers
Return on Equity (TTM)
-148.70%vs Biotechnology peers
Revenue (TTM)
2.79MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0340USDUpdated Sep 27, 2026Quarterly Revenue Growth
-90.50%vs Biotechnology peers
Gross Profit (TTM)
-257.47MUSDvs all stocks (USD)
EBITDA (TTM)
-314.38MUSDvs all stocks (USD)
Net Income (TTM)
-306.64MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-90.49%vs Biotechnology peers
Operating Cash Flow (TTM)
-267.30MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-155.01MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
31.37MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
2.07MUSDFY2025 · Dec 31, 2025Gross Profit
29.30MUSDFY2025 · Dec 31, 2025Operating Income
-243.43MUSDvs all stocks (USD)
Pre-tax Income
-231.68MUSDFY2025 · Dec 31, 2025Income Tax Expense
279.00KUSDFY2025 · Dec 31, 2025Net Income
-231.96MUSDFY2025 · Dec 31, 2025EBIT
-231.65MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-229.34MUSDFY2025 · Dec 31, 2025Research & Development
221.04MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
51.70MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.78MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
33.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.17USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.17USDFY2025 · Dec 31, 2025Basic Shares Outstanding
73.25MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
73.25MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-231.96MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-244.79MUSDFY2025 · Dec 31, 2025Free Cash Flow
-247.91MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
101.97MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-231.96MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.31MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
279.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
27.87MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-4.83MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.67MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-27.79MUSDFY2025 · Dec 31, 2025Capital Expenditures
-3.13MUSDFY2025 · Dec 31, 2025Purchase of Investments
-252.02MUSDFY2025 · Dec 31, 2025Sale of Investments
323.73MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
68.58MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-105.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.93MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
171.41MUSDFY2025 · Dec 31, 2025Shares Outstanding
84.98MSharesUpdated Sep 27, 2026Float Shares
60.67MSharesUpdated Sep 27, 2026Shares Short
19.81MSharesUpdated Sep 27, 2026Short Ratio
2.78daysvs all stocks
Short % of Shares Outstanding
24.18%vs all stocks
% Held by Insiders
3.52%vs all stocks
% Held by Institutions
117.66%vs all stocks
Total Cash (MRQ)
180.47MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.09USDUpdated Sep 27, 2026Total Debt (MRQ)
22.37MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1344xvs Biotechnology peers
Current Ratio (MRQ)
4.50xvs Biotechnology peers
Book Value per Share (MRQ)
1.96USDUpdated Sep 27, 2026Total Assets
364.00MUSDvs all stocks (USD)
Total Current Assets
328.65MUSDFY2025 · Dec 31, 2025Total Liabilities
57.88MUSDFY2025 · Dec 31, 2025Total Non-current Assets
35.34MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
20.86MUSDFY2025 · Dec 31, 2025Total Current Liabilities
37.02MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
101.82MUSDFY2025 · Dec 31, 2025Other Short-term Investments
204.26MUSDFY2025 · Dec 31, 2025Accounts Receivable
651.00KUSDFY2025 · Dec 31, 2025Inventory
1.81MUSDFY2025 · Dec 31, 2025Accounts Payable
10.49MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
2.14MUSDFY2025 · Dec 31, 2025Long-term Debt
20.77MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
87.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
83.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.10BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
306.11MUSDvs all stocks (USD)
52-Week Low
3.42USDUpdated Sep 27, 202652-Week High
19.11USDUpdated Sep 27, 202652-Week Change
-74.23%vs all stocks
Beta
1.64xvs all stocks
50-Day MA
8.16USDUpdated Sep 27, 2026200-Day MA
12.94USDUpdated Sep 27, 2026Avg 10-Day Volume
4.05MSharesUpdated Sep 27, 2026Avg 30-Day Volume
6.20MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-3.75USDUpdated Sep 27, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 100%, higher than 95% of its Biotechnology peers (median 67.2%)Significant
Gross margin: 1.00Industry median: 0.67Industry P95: 1.00Peers compared: 260
Operating margin is -19207.1%, lower than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: -192.071Industry median: -0.38Industry P5: -43.63Peers compared: 260
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 4.50Altman Z-Score: -2.16
Financial Health
Altman Z-Score -2.16: distress zoneCritical
Altman Z-Score: -2.16
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $2.79M, lower than 95% of all stocks globallySignificant
Revenue (USD): 2,788,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Hikal Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Essex Bio-Technology Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Century Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
JBM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lavipharm S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Anhui Huangshan Capsule Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Hile Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sab Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
AtaiBeckley Inc.
Tier 1ProductionApproval-Gated PipelineRule
Evommune, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Eos Energy Enterprises Inc.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Red Cat Holdings, Inc.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Veritone, Inc.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown